Martin Shkreli speaks during an interview with Bloomberg on Friday, Dec. 23, 2016. Shkreli said the national outrage over drug pricing was blown out of proportion and heightened by the U.S. presidential election, although he conceded he could have predicted the blowback better. Victor J. Blue/Bloomberg via Getty Images
Martin Shkreli has a date with prosectors at the federal courthouse in two months, but the notorious biotech entrepreneur still has time to talk with reporters. And it turns out he’s working on yet another biotech startup as his lawyers prepare to defend him on criminal fraud charges.
The reporter in this case was Sheelah Kolhatkar from The New Yorker. They met in a Manhattan bar, where Shkreli confidently predicted his looming exoneration on fraud charges.
“I think they’ll return a not-guilty verdict in two hours,” he told Kolhatkar. “There are going to be jurors who will be fans of mine. I walk down the streets of New York and people shake my hand. They say, ‘I want to be just like you.’”
Shkreli never has faced more than a scolding from lawmakers for the 5000% hike in the price of Daraprim, an old drug he acquired after founding Turing. Caught in the bright glare of a scandal, online mobs shrieking digital abuse, Shkreli turned obscenely defiant on Twitter — which later banned him — and never did back down from the price. He was forced to give up the CEO’s job after the fraud charges hit.
Shkreli, though, is clearly committed to his future as a serial entrepreneur.
In the interview he mentioned a new biotech software company he is hatching. This new venture is called Gödel Systems, but he’s stingy on details.
According to a recent SEC filing, Shkreli and his confederates have raised $50,000 of a $1 million raise, lunch money compared to the larger sums raised for Turing and his first startup, Retrophin, which sued him.
He is, though, happy to predict the stunning impact it will have.
“I haven’t told anybody what it is,” he said. “When I do, it will shock and awe the world.”
You’ve been warned.
After we published on Wednesday, Shkreli sent me a reply. Seeing as he’s been banned from Twitter, it seems only fair to add it here:
Lol you love disinformation – it must be a loss-of-function mutation – do not reproduce
He is very consistent.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.